40 Recruiting Studies Using Anastrozole
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Anastrozole
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
📍 Marin Cancer Care, Inc — Greenbrae, California
Breast Cancer
View Study & Checklist ➔OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
📍 Clinical Trial Site — Tucson, Arizona
Breast Cancer
View Study & Checklist ➔A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
📍 Highlands Oncology Group - Duplicate 2 — Springdale, Arkansas
Non Small Cell Lung Cancer
View Study & Checklist ➔An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
📍 Research Site — Dothan, Alabama
Breast Cancer, Early Breast Cancer
View Study & Checklist ➔A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
📍 Research Site — Commack, New York
Metastatic Breast Cancer
View Study & Checklist ➔S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
📍 Northeast Alabama Regional Medical Center — Anniston, Alabama
Breast Ductal Carcinoma In Situ
View Study & Checklist ➔Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Estrogen Receptor-positive Breast Cancer
View Study & Checklist ➔Roll-over Study to Allow Continued Access to Ribociclib
📍 Ironwood Cancer and Research Centers — Chandler, Arizona
Metastatic Breast Cancer
View Study & Checklist ➔A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
📍 Highlands Oncology Group - Duplicate 2 — Rogers, Arkansas
Breast Neoplasms
View Study & Checklist ➔Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
📍 UCSF — San Francisco, California
HER-2 Positive Breast Cancer
View Study & Checklist ➔Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
📍 Northeast Alabama Regional Medical Center — Anniston, Alabama
Breast Adenocarcinoma
View Study & Checklist ➔TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
📍 Stamford Hospital — Stamford, Connecticut
Breast Cancer
View Study & Checklist ➔A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
📍 Research Site — Mobile, Alabama
ER-Positive HER2-Negative Breast Cancer
View Study & Checklist ➔A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
📍 Eastern Cooperative Oncology Group — Boston, Massachusetts
Estrogen Receptor-positive Breast Cancer
View Study & Checklist ➔Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
📍 Levine Cancer Institute — Charlotte, North Carolina
Female Breast Carcinoma
View Study & Checklist ➔Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
📍 Research Site — Phoenix, Arizona
ER-Positive HER2-Negative Breast Cancer
View Study & Checklist ➔Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
📍 Mount Sinai Beth Israel Comprehensive Cancer Center West — New York, New York
Breast Neoplasms
View Study & Checklist ➔PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
📍 University of Alabama — Birmingham, Alabama
Breast Neoplasms
View Study & Checklist ➔A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
Breast Cancer
View Study & Checklist ➔A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
📍 USO - Southern Cancer Center — Daphne, Alabama
Breast Neoplasms
View Study & Checklist ➔The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans
📍 University of British Columbia - Okanagan — Kelowna, British Columbia
Cerebral Blood Flow
View Study & Checklist ➔ETHAN - ET for Male BC
📍 Georgetown University Medical Center — Washington D.C., District of Columbia
Male Breast Cancer
View Study & Checklist ➔Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
📍 Siteman Cancer Center at Washington University — St Louis, Missouri
Anatomic Stage III Breast Cancer AJCC v8
View Study & Checklist ➔A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
📍 Mayo Clinic of Scottsdale — Scottsdale, Arizona
Breast Cancer
View Study & Checklist ➔A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
📍 Southern Cancer Center, PC — Daphne, Alabama
Breast Cancer
View Study & Checklist ➔Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
📍 NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist ➔Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Recurrent Endometrial Carcinoma
View Study & Checklist ➔First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
📍 Ellison Clinic at Saint John's — Los Angeles, California
Breast Cancer
View Study & Checklist ➔Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
📍 Washington University School of Medicine — St Louis, Missouri
Breast Cancer
View Study & Checklist ➔A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
📍 Alaska Oncology and Hematology — Anchorage, Alaska
Breast Neoplasms
View Study & Checklist ➔NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
📍 Washington University School of Medicine — St Louis, Missouri
Breast Cancer
View Study & Checklist ➔A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
📍 HonorHealth — Phoenix, Arizona
Low Grade Serous Ovarian Cancer
View Study & Checklist ➔Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
Breast Cancer
View Study & Checklist ➔Study of 18F-FFNP Breast PET/MRI
📍 UW Carbone Cancer Center — Madison, Wisconsin
Breast Cancer
View Study & Checklist ➔Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Locoregional Recurrence
View Study & Checklist ➔Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
📍 St. Joseph Heritage Healthcare — Fullerton, California
Early-stage Breast Cancer
View Study & Checklist ➔A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
📍 Research Site — Birmingham, Alabama
Breast Cancer, Early Breast Cancer
View Study & Checklist ➔Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
📍 Northwestern Memorial Hospital — Chicago, Illinois
Inguinal Hernia Unilateral
View Study & Checklist ➔Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
📍 Research Site — Gilbert, Arizona
Advanced Breast Cancer
View Study & Checklist ➔